Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company developing RNA- and protein-based medicines using its Endosomal Escape Vehicle (EEV™) technology. The news flow around Entrada centers on its neuromuscular and ocular pipelines, corporate updates and collaboration activities.
Investors following TRDA news can track detailed updates on the company’s Duchenne muscular dystrophy (DMD) franchise, including the ELEVATE-44-201 and ELEVATE-45-201 global Phase 1/2 multiple ascending dose studies of ENTR-601-44 and ENTR-601-45, and the planned development of ENTR-601-50 and ENTR-601-51. Company announcements describe milestones such as first patient dosing, cohort completion, regulatory authorizations in the U.K. and EU, and expectations for future data readouts.
News releases also highlight Entrada’s expansion into ocular and metabolic diseases, including preclinical progress and the nomination of ENTR-801 as the first ocular clinical candidate for Usher syndrome type 2A. Additional coverage includes updates on the VX-670 collaboration for myotonic dystrophy type 1, quarterly financial results furnished via Form 8-K, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), leadership appointments and participation in healthcare and investor conferences.
By reviewing Entrada Therapeutics news, readers can follow how the company reports on its clinical-stage programs, regulatory interactions, financial position and patient-focused initiatives such as the DREAMS Grant Program. This page aggregates press releases and related disclosures so that followers of TRDA can see how the pipeline and corporate activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Entrada Therapeutics (Nasdaq: TRDA) has appointed Dr. Bernhardt “Bernie” Zeiher to its Board of Directors. Previously, Dr. Zeiher was the Chief Medical Officer at Astellas Pharma, where he played key roles in developing numerous therapeutic products. His extensive experience in clinical and regulatory affairs is expected to benefit Entrada as it progresses its lead drug programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1. Dr. Zeiher expresses enthusiasm for joining during this growth phase, emphasizing his alignment with Entrada’s mission to innovate in intracellular therapeutics.
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company, announced participation of CEO Dipal Doshi in a virtual fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023 at 9:00 a.m. ET. This event aims to highlight Entrada's innovative approach to Endosomal Escape Vehicle (EEV™) therapeutics, which targets previously inaccessible intracellular areas for drug delivery. Interested stakeholders can access the live webcast on Entrada's Investor Relations page, with a replay available for 90 days post-event.
Entrada is developing therapies for various diseases, including neuromuscular and immunological conditions, with specific focus on treatments for Duchenne muscular dystrophy.
Entrada Therapeutics (TRDA) has announced a collaboration with Vertex to develop Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1. The company is actively addressing the FDA's clinical hold on its IND application for ENTR-601-44 and has selected ENTR-601-45 as a new therapeutic candidate for Duchenne muscular dystrophy. Following the Vertex collaboration, Entrada's cash runway has been extended into the second half of 2025. Financial results for Q4 2022 reveal a net loss of $24.6 million, up from $18.4 million in Q4 2021, with cash and equivalents totaling $188.7 million, down from $291.1 million a year prior.
Entrada Therapeutics (Nasdaq: TRDA) recently announced that its President and CEO, Dipal Doshi, will participate in the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The conference aims to discuss advancements in healthcare, particularly in biotechnology. A live webcast of the panel will be accessible on Entrada's Investor Relations website, with a replay available for 90 days post-event. Entrada specializes in Endosomal Escape Vehicle (EEV™) therapeutics, targeting previously inaccessible diseases, with a focus on neuromuscular disorders.
Entrada Therapeutics (Nasdaq: TRDA) has announced the successful closing of its strategic collaboration with Vertex following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes a $224 million upfront payment and a $26 million equity investment. Entrada could earn up to $485 million in milestone payments and royalties on future product sales. The collaboration focuses on ENTR-701, a candidate for treating myotonic dystrophy type 1 (DM1), and extends the company’s cash runway into the second half of 2025, enabling further development of its Endosomal Escape Vehicle (EEV™)-therapeutics.